Search Results
Your search for cutaneous squamous cell carcinoma matches 113 pages
Showing 101 - 113Evidence of Basal to Squamous Cell Phenotype Switch Under Vismodegib Treatment for Basal Cell Carcinoma
In a letter to The New England Journal of Medicine, Ransohoff et al describe genetic evidence of phenotype switching from basal cell to squamous cell carcinoma in a patient receiving vismodegib (Erivedge) for basal cell carcinoma. Hedgehog signaling pathway activation, a central feature of...
Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients
Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...
Dabrafenib Plus Trametinib Improves Overall Survival vs Dabrafenib in BRAF V600–Mutant Melanoma
Overall survival results of a phase III COMBI-d trial reported in The Lancet by Long et al showed that the combination of the BRAF inhibitor dabrafenib (Tafinlar) with the MEK inhibitor trametinib (Mekinist) resulted in significantly prolonged overall survival vs dabrafenib alone in patients with...
Improved Overall Survival in Metastatic Melanoma With First-Line Dabrafenib Plus Trametinib
In a phase III study reported in The New England Journal of Medicine, Robert et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor trametinib (Mekinist) significantly improved overall survival compared with the BRAF inhibitor vemurafenib (Zelboraf) in...
BRAF Inhibitor Dabrafenib Plus MEK Inhibitor Trametinib Improves Outcomes vs Dabrafenib Alone in Previously Untreated BRAF-Mutant Advanced Melanoma
In a phase III trial reported in The New England Journal of Medicine, Long and colleagues found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) improved response rate and progression-free survival compared with dabrafenib alone in...
BRAF Inhibitor Vemurafenib Plus MEK inhibitor Cobimetinib vs Vemurafenib Alone in Previously Untreated BRAF-Mutant Advanced Melanoma
In a phase III trial reported in The New England Journal of Medicine, Larkin and colleagues found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib improved response rate and progression-free survival compared with vemurafenib alone in...
Promising Phase Ib Findings With Combined BRAF and MEK Inhibition With Vemurafenib and Cobimetinib in Advanced BRAF V600–Mutant Melanoma
In a phase Ib study reported in The Lancet Oncology, Ribas et al found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib was safe and active in the treatment of advanced BRAF V600–mutant melanoma. Preclinical studies have shown that the...
Total Parotidectomy May Benefit Patients With Cutaneous Squamous Cell Carcinoma or Malignant Melanoma With Metastasis to the Parotid Superficial Lobe
The optimal extent of surgical resection is unclear in patients with parotid superficial lobe lymph node metastasis from cutaneous squamous cell carcinoma and malignant melanoma. In a single-institution retrospective review reported in JAMA Otolaryngology Head & Neck Surgery, Thom et al found...
‘Real World’ Safety Study of Vemurafenib in BRAF V600–Mutated Metastatic Melanoma Shows Similar Safety Profile as Pivotal Trials
As reported in The Lancet Oncology by Larkin et al, interim results of a safety study designed to reflect the spectrum of patients encountered in routine practice suggest that vemurafenib (Zelboraf) has a safety profile in patients with BRAF V600–mutated metastatic melanoma similar to that...
Extended Follow-up in BRIM-3 Shows Prolonged Survival With Vemurafenib in BRAF V600E/K Mutation–Positive Melanoma
In the BRIM-3 trial, vemurafenib (Zelboraf) was associated with improved progression-free and overall survival vs dacarbazine in patients with advanced BRAF V600 mutation–positive melanoma. In an extended follow-up reported in The Lancet Oncology, McArthur et al found that superior survival...
Enhanced Treatment, Surveillance Needed for Certain Melanoma Patients to Prevent Secondary Cancers, Researchers Say
Researchers at Moffitt Cancer Center in Tampa, Florida, suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy with other inhibitors, especially as they become...
Enhanced Treatment, Surveillance Needed for Patients With BRAF-Mutant Melanoma to Prevent Secondary Cancers
Researchers at Moffitt Cancer Center suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF inhibitor therapy with other inhibitors, especially as they become more widely used....
FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer
The U.S. Food and Drug Administration today approved two new drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), for patients with advanced or unresectable melanoma, the most dangerous type of skin cancer. Dabrafenib, a BRAF inhibitor, is approved to treat patients with melanoma whose tumors...
